Amine Oxidase Inhibitors and Development of Neuroprotective Drugs

Title: Amine Oxidase Inhibitors and Development of Neuroprotective Drugs

Volume: 2 Issue: 2

Author(s): Bernard N. Sowa, Kathryn G. Todd, A. M. I Tanay, Andrew Holt and Glen B. Baker

Affiliation:

• Department of Psychiatry, 1E7.31 Mackenzie Centre, University of Alberta, Edmonton, AB, Canada T6G 2B7.,Canada

Keywords: neuroprotection, neurorescue, l-deprenyl, amine oxidase, semicarbazide-sensitive amine oxidase, phenelzine, phenylethylidenehydrazine

Abstract: Monoamine oxidase (MAO) inhibitors continue to be used for treatment of a number of psychiatric and neurologic disorders. In recent years, inhibitors of MAO and other amine oxidases have received considerable attention because of their neuroprotective and neurorescue effects in such models as oxygen-glucose deprivation in vitro, thiamine deficiency, NMDA-instigated excitotoxicity, free radical-mediated oxidative stress, cerebral ischemia, and experimental models of Alzheimers and Parkinsons Diseases. This review focuses on the MAO inhibitors l-deprenyl, tranylcypromine and phenelzine and the possible mechanisms underlying their neuroprotective actions. In addition, there is a discussion of analogs of phenelzine and l-deprenyl as inhibitors of other amine oxidases, including semicarbazide-sensitive amine oxidase (SSAO), and their possible involvement in neuroprotection.

Cite this article as:

Sowa N. Bernard, Todd G. Kathryn, I Tanay M. A., Holt Andrew and Baker B. Glen, Amine Oxidase Inhibitors and Development of Neuroprotective Drugs, Current Neuropharmacology 2004; 2(2) . https://dx.doi.org/10.2174/1570159043476800